GHK-Cu vs OS-01 (OneSkin Peptide)

GHK-Cu and OS-01 (OneSkin Peptide) represent two distinct approaches to skin research. GHK-Cu, a naturally occurring copper-binding tripeptide, has been extensively studied since its discovery in 1973 for roles in wound healing, collagen synthesis, and gene modulation, with a broad safety profile supported by decades of cosmetic and clinical use. In contrast, OS-01 is a proprietary peptide developed by OneSkin, identified through high-throughput screening for its senolytic and senomorphic activity targeting cellular senescence in skin cells. Research indicates that GHK-Cu operates through multiple pathways, including modulation of matrix metalloproteinases and antioxidant responses, while OS-01 focuses on reducing the biological age of skin by clearing senescent cells. This comparison highlights their differing mechanisms, evidence levels, and research applications, providing a framework for researchers to evaluate which peptide aligns with their experimental goals.

GHK-Cu (glycyl-L-histidyl-L-lysine) is a naturally occurring tripeptide that binds copper, first identified by Dr. Loren Pickart in 1973. Plasma levels average 200 ng/mL at age 20 but decline to approximately 80 ng/mL by age 60, suggesting an age-related decrease in endogenous availability. Mechanistically, GHK-Cu has been shown to enhance collagen synthesis, promote wound healing, and modulate gene expression, including upregulation of antioxidant enzymes and downregulation of pro-inflammatory cytokines. Preclinical models indicate it stimulates fibroblast proliferation and angiogenesis, contributing to tissue regeneration. The evidence base is robust, with decades of cosmetic use and clinical research supporting its safety and efficacy. Key research claims include improved skin firmness and elasticity, reduced fine lines and wrinkles, and accelerated wound healing. Its molecular weight is approximately 340 g/mol (as the copper complex), with the formula C14H24N6O4Cu.

OS-01 is a proprietary peptide developed by OneSkin, identified through a high-throughput screen of peptide libraries for senolytic and senomorphic activity. Senolytic agents selectively eliminate senescent cells, while senomorphic compounds suppress the senescence-associated secretory phenotype (SASP). In preclinical studies, OS-01 has been shown to reduce markers of cellular senescence in skin cells, such as p16INK4a and SA-β-galactosidase, and to decrease the expression of pro-inflammatory SASP factors. Research suggests that topical application of OS-01 may reduce the biological age of skin, as measured by epigenetic clocks and other biomarkers. However, the evidence base is more limited compared to GHK-Cu, with fewer independent studies and a shorter history of use. The peptide is currently used in OneSkin's topical product line, and available studies indicate it is well-tolerated. Further research is needed to fully elucidate its mechanism and long-term effects.

Both GHK-Cu and OS-01 are investigated for their potential in skin health and anti-aging research. GHK-Cu has a broader range of studied applications, including wound healing, where it has been shown to accelerate tissue repair and reduce inflammation in preclinical models. OS-01, in contrast, is primarily studied for its senolytic effects on skin aging, with no additional unique applications reported in the literature. Researchers interested in general skin regeneration and collagen modulation may find GHK-Cu more suitable, while those focused on targeting cellular senescence as a driver of skin aging may prefer OS-01. The overlap in anti-aging applications suggests potential for comparative studies, but the distinct mechanisms warrant careful experimental design.

GHK-Cu has an excellent safety profile, with minimal side effects reported in decades of cosmetic use and clinical research (PMID: 29986520). Topical forms are generally well-tolerated, though mild skin irritation is rare and typically limited to very sensitive skin. Injectable forms may cause mild injection site reactions, lightheadedness, nausea, or flu-like symptoms; rotating injection sites can reduce local irritation. OS-01 is reported to be well-tolerated in available studies, but the evidence base is smaller, and long-term safety data are limited. Researchers should consider the maturity of the safety profile when selecting a peptide for extended studies. GHK-Cu's extensive history provides greater confidence in its safety, while OS-01 requires cautious interpretation due to fewer published safety assessments.